Clinical trial NCT00967616: Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Official title: Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Colorectal Cancer
Neoplasms, Colorectal
Keywords: metastatic
colon
rectum
combination
chemotherapy
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2009-08-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America. Adult subjects with metastatic colorectal cancer (CRC) who failed first-line chemotherapy will participate in the study, which will be conducted on an outpatient basis. It is anticipated that 100 subjects will be enrolled to obtain approximately 90 evaluable subjects.


Eligibility criteria: Inclusion Criteria:

* Metastatic CRC that has progressed following first-line therapy.
* Measurable disease (Response Evaluation Criteria in Solid Tumors \[RECIST\], Version 1.0.
* Male or female ≥ 18 years of age.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, Version 3.0, grade ≤ 1.
* Adequate organ and bone marrow function as evidenced by:

  * Hemoglobin ≥ 9 g/dL (transfusion and/or growth factor support allowed)
  * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
  * Platelet count ≥ 100 x 10\^9/L
  * Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min
  * Aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN in participants with no liver metastasis and ≤ 5.0 x ULN in participants with liver metastasis
  * Total bilirubin ≤ 1.5 x ULN
* Women of childbearing potential must be willing to consent to using effective contraception (eg, hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for at least 3 months thereafter. Men who are the partner of a woman of childbearing potential must be willing to consent to using effective contraception (eg, vasectomy or barrier with spermicide) while on treatment and for 3 months thereafter.
* All female participants of childbearing potential must have a negative pregnancy test (serum or urine) result before initiating study treatment.
* Participants must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Independent Ethics Committee (IEC)- or Institutional Review Board (IRB)-approved informed consent form (ICF) (including HIPAA authorization, if applicable) before performance of any study-specific procedures or tests.
* Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

* First-line treatment with an irinotecan-based regimen (eg, FOLFIRI).
* Anticipation of need for a major surgical procedure or radiation therapy (RT) during the study.
* Treatment with chemotherapy, other thiazolidinediones (TZD), RT, surgery, immunotherapy, biological therapy, or any investigational anticancer agent within 4 weeks before start of study treatment.
* History of any of the following conditions within 6 months before initiating study treatment:

  * Diabetes mellitus requiring treatment with insulin or TZD agents
  * Myocardial infarction with significant impairment of cardiac function (eg, ejection fraction ≤ 50%)
  * Severe/unstable angina pectoris
  * Coronary/peripheral artery bypass graft
  * New York Heart Association (NYHA) class III or IV congestive heart failure
  * Malabsorption syndrome, chronic diarrhea (lasting \> 4 weeks), inflammatory bowel disease, or partial bowel obstruction.
* Participants with clinically active brain metastases (defined as untreated, symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms); uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis. Participants with treated brain metastasis will be included in the study if they have recovered from the acute, toxic effects of RT. A minimum of 15 days must have elapsed between the end of RT and enrollment into the study.
* History of malignancy other than CRC, unless there is an expectation that the malignancy has been cured, and tumor-specific treatment for the malignancy has not been administered within the previous 5 years.
* Clinically significant, severe, active infection requiring IV antibiotic or antiviral agents.
* Pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Participants with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor.
* Need for concomitant use of other TZD agents during the study.
* Previous administration of CS-7017.
* Pregnant or breast feeding.
* Known to be homozygous for the UGT1A1\*28 allele.
* Known history of severe hypersensitivity reactions to any of the components of CS-7017, irinotecan, leucovorin, or 5-FU.
* Serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the Investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment.

Primary outcomes:
measure: Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
timeFrame: Baseline to 16 weeks postdose
Secondary outcomes:
measure: Median Overall Progression-Free Survival Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
timeFrame: Baseline to approximately 3 years postdose
measure: Median Overall Progression-Free Survival: Sensitivity Analysis Including Clinical Progression After Administration of CS-7017 and Irinotecan, Leucovorin, and 5-Fluorouracil After Failure of First-line Therapy of Metastatic Colorectal Cancer
timeFrame: Baseline to approximately 3 years postdose
measure: Best Overall Response and Objective Response Rate Following Administration of CS-7017 in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
timeFrame: Baseline to approximately 3 years postdose
measure: Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer
timeFrame: Baseline to 30 days post last dose, up to approximately 3 years
Other outcomes:
Locations:
city: Beverly Hills
country: United States
facility: Beverly Hills Cancer Center
state: California
city: Fullerton
country: United States
facility: St. Jude Heritage Medical Group
state: California
city: Washington
country: United States
facility: John Marshall
state: District of Columbia
city: Atlanta
country: United States
facility: Georgia Cancer Specialists
state: Georgia
city: Bethesda
country: United States
facility: Victor Priego
state: Maryland
city: Canton
country: United States
facility: Gabrail Cancer Center
state: Ohio
city: Buenos Aires
country: Argentina
facility: Instituto FIDES Oncologia y Especialidades Medicas
city: Tucuman
country: Argentina
facility: CAIPO Centro para la Atencion Integral del Paciente Oncologico
city: Porto Alegre
country: Brazil
facility: Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul - PUC-RS
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional de Cancer INCA
city: Sao Paulo
country: Brazil
facility: ICAVC
city: Santiago
country: Chile
facility: Fundacion Arturo Lopez Perez
city: Santiago
country: Chile
facility: Instituto Nacional del Cancer
city: Vina del Mar
country: Chile
facility: Instituto Oncologico Clinica Renaca
city: Callao
country: Peru
facility: Hospital Nacional Alberto Sabogai Sologuren
city: Lima
country: Peru
facility: Hospital Nacional Dos de Mayo
city: Lima
country: Peru
facility: Oncosalud SAC
city: Lima
country: Peru
facility: Hospital Nacional Dos de Mayo
Study officials:
References: